KBC Group NV Boosts Position in Eli Lilly and Company (LLY)
KBC Group NV raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 117.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 757,289 shares of the company’s stock after buying an additional 409,273 shares during the period. Eli Lilly and makes up about 0.6% of KBC Group NV’s holdings, making the stock its 29th largest position. KBC Group NV owned 0.07% of Eli Lilly and worth $63,696,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in LLY. First Command Financial Services Inc. raised its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co purchased a new position in shares of Eli Lilly and during the first quarter valued at about $135,000. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Eli Lilly and during the first quarter valued at about $179,000. Finally, Alpha Windward LLC raised its position in shares of Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the last quarter. Institutional investors own 75.59% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.94% during mid-day trading on Friday, hitting $77.07. The stock had a trading volume of 4,061,282 shares. The stock has a market cap of $81.31 billion, a P/E ratio of 33.35 and a beta of 0.34. The company’s 50 day moving average is $82.39 and its 200-day moving average is $81.90. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.86 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/19/kbc-group-nv-has-63-70-million-stake-in-eli-lilly-and-company-lly-updated-updated-updated.html.
A number of research firms have recently weighed in on LLY. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a report on Wednesday. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $88.27.
In related news, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is currently owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.